New combo therapy takes aim at Hard-to-Treat salivary gland cancer
NCT ID NCT07579598
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a combination of an antibody-drug conjugate (a targeted cancer drug) and stereotactic body radiotherapy (precise, high-dose radiation) in 40 people with recurrent or metastatic salivary gland cancer. Participants first receive the drug; if their disease stabilizes or shows limited progression, they also get radiation. The goal is to see if this approach shrinks tumors or controls the disease longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Becotatug Vedotin (antibody-drug conjugate) and stereotactic body radiotherapy
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced salivary gland cancer that has spread or come back after standard therapy.
- What could go wrong
- This is a small, early-phase exploratory study with only 40 participants. It may not show enough benefit to move forward, and side effects from the drug or radiation could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Can a pill target multiple Hard-to-Treat cancers?